Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
Globe Newswire•17/09/2026•16:01 ET
0
Get started
Create a free account to read the full story and Whiz Insights.
Create a free account to read the full story and Whiz Insights.